
- Past Issues
- e-Submission
-
2021 Impact Factor 1.766
5-Year Impact Factor 1.674
Editorial Office
- +82-01-9989-7744
- kbiolpsychiatry@gmail.com
- https://www.biolpsychiatry.or.kr/
2021 Impact Factor 1.766
5-Year Impact Factor 1.674
Korean Journal of Biological Psychiatry 1997;4(1):127-31. Published online: Jan, 1, 1997
Objective:To evaluate the clinical efficacy of adjuvant sertraline treatment in chronic schizophrenic patients, we carried out a double-blind, placebo controlled study.
Method:Thirty six inpatients who fulfilled DSM-III-R criteria for chronic schizophrenia were randomly assigned to sertraline and placebo groups in a double-blinded fashion. A history of at least 2 years of illness and at least six months of hospitalization were prerequisities for inclusion in the study. Patients were received sertraline 50mg or placebo for 8 weeks in addition to their routine haloperidol regimen. Positive and Negative Syndrome Scale(PANSS), Clinical Global Impression(CGI), Simpson-Angus Scale(S-A) were evaluated at 5 points;baseline, 2, 4, 6, and 8 weeks of treatment.
Results:The groups were controlled for age, gender, and length of illness. There were no significant differences in three PANSS factros(positive, negative, general), CGI, and S-A scale scores at any between sertaline and placebo treatment.
Conclusion:This placebo controlled study showed no significant effects of sertraline on negative and positive symptoms in chronic schizophrenic patients.
Keywords Chronic schizophrenia;Double-blind;Sertraline;Haloperidol.